Welcome to our dedicated page for Avalo Therapeutics news (Ticker: AVTX), a resource for investors and traders seeking the latest updates and insights on Avalo Therapeutics stock.
Avalo Therapeutics, Inc. reports developments for a clinical-stage biotechnology company focused on IL-1β-based treatments for immune-mediated inflammatory diseases. Its recurring updates center on abdakibart (AVTX-009), an anti-IL-1β monoclonal antibody evaluated in hidradenitis suppurativa, including LOTUS trial results, safety and efficacy disclosures, and program development plans.
Company news also covers financial results, investor presentations and conferences, equity compensation grants, public financing activity involving common stock and pre-funded warrants, and milestone obligations tied to the AlmataBio acquisition. These updates connect Avalo's clinical pipeline, capital needs, and governance actions to its public-company reporting cycle.
Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced that its senior management team will present at the Jefferies Next Generation IBD Therapeutics Summit on October 19, 2021. A pre-recorded webcast of the presentation will be available starting at 8:00 AM ET on the same day, accessible via the Investor section of the company's website. Avalo focuses on developing targeted therapeutics for unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases, aiming to deliver impactful medical solutions.
Horizon Technology Finance Corporation (NASDAQ: HRZN) reported strong performance for Q3 2021, achieving a record $141 million in loan originations, with $99 million attributed to HRZN. The portfolio ended with a committed backlog of $123 million, reflecting robust demand for venture loans. During the quarter, HRZN received $50 million in loan prepayments, boosting fee and interest income. The company closed new loan commitments totaling $91 million, with a significant pipeline of opportunities, suggesting ongoing growth potential for shareholders.
Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced that its senior management will present in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference, scheduled for September 29, 2021, at 2:00 PM ET. This engaging session will provide insights into the company's precision medicine initiatives targeting unmet clinical needs in immunology and rare diseases. A live webcast will be available on the company's website under the 'News/Events' section.
Avalo Therapeutics (AVTX) has successfully closed its underwritten offering of common stock, selling a total of 14,308,878 shares at a public offering price of $2.20 each. This offering raised approximately $31.5 million in gross proceeds before expenses. The shares were sold under an effective registration statement with the SEC, and Jefferies and RBC Capital Markets acted as joint book-running managers for the offering. The funds will support Avalo's commitment to developing targeted therapeutics for patients with unmet medical needs.
Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced an underwriting agreement with Jefferies LLC and RBC Capital Markets for a public offering of 12,500,000 shares at $2.20 each, expected to close around September 17, 2021. If the underwriters exercise their option, total gross proceeds could reach approximately $31.6 million. The proceeds will be used for working capital and general corporate purposes. The offering is made under an effective shelf registration statement previously filed with the SEC.
Avalo Therapeutics (Nasdaq: AVTX) announced its intention to conduct an underwritten public offering of common stock, with a potential 30-day option for underwriters to purchase an additional 15%. The offering aims to raise funds for working capital and general corporate purposes, and will be executed under an effective shelf registration statement. Jefferies and RBC Capital Markets serve as joint book-running managers. The offering is subject to market conditions, with no guarantee of completion or specific terms.